Consensus Conference on Acute Bronchiolitis (I): Methodology and Recommendations;Conferencia de Consenso sobre bronquiolitis aguda (I): metodología y recomendaciones

Anales de Pediatria

Volumn 72, Issue 3, 2010, Pages

  Gonzalez de Dios J ^a   Ochoa Sangrador, C ^b  

^a HOSPITAL DE TORREVIEJA   (Spain)

^b HOSPITAL VIRGEN DE LA CONCHA   (Spain)

Author keywords

Consensus development conference; Pediatrics; Systematic review; Viral bronchiolitis

Indexed keywords

ADRENALIN; ANTIBIOTIC AGENT; BRONCHODILATING AGENT; CORTICOSTEROID; FUROSEMIDE; HELIOX; IMMUNOGLOBULIN; IPRATROPIUM BROMIDE; METHYLXANTHINE; MONTELUKAST; PALIVIZUMAB; RIBAVIRIN; SALBUTAMOL; SURFACTANT; TERBUTALINE;

ANTIBIOTIC THERAPY; APNEA; ARTICLE; ASSISTED VENTILATION; BACTERIAL INFECTION; BACTERIUM IDENTIFICATION; BRONCHIOLITIS; CLINICAL EFFECTIVENESS; CONSENSUS DEVELOPMENT; COST EFFECTIVENESS ANALYSIS; DISEASE SEVERITY; DRUG COST; ECONOMIC ASPECT; FLUID THERAPY; HIGH RISK PATIENT; HUMAN; IMMUNOTHERAPY; INCIDENCE; INFECTION PREVENTION; INFECTION RISK; OXYGEN SATURATION; OXYGEN THERAPY; PHYSIOTHERAPY; POPULATION RESEARCH; POSITIVE END EXPIRATORY PRESSURE; RESPIRATORY FAILURE; RESPIRATORY TRACT INFECTION; RISK ASSESSMENT; RISK FACTOR; SCREENING TEST; THORAX RADIOGRAPHY; VIRUS DIAGNOSIS; VIRUS INFECTION;

ACUTE DISEASE; BRONCHIOLITIS; CHILD; HUMANS; RISK FACTORS; SEVERITY OF ILLNESS INDEX;

EID: 77649336327     PISSN: 16954033     EISSN: 16959531     Source Type: Journal    
DOI: 10.1016/j.anpedi.2009.11.020     Document Type: Article

References (118)

1. McConnochie K.M. Bronchiolitis. What's in the name?. Am J Dis Child 137 (1983) 11-13
2. González de Dios J, Ochoa Sangrador C, y Grupo Investigador del Proyecto aBREVIADo. Estudio de variabilidad en el manejo de la bronquiolitis aguda en España en relación con la edad de los pacientes. Estudio multicéntrico nacional (Proyecto aBREVIADo). An Pediatr (Barc). 2010; 72: 4-18.
3. Figueras Aloy J., López Sastre J., Medrano López C., Bermúdez-Cañete Fernández R., Fernández Pineda L., Bonillo Perales A., et al. Consenso multidisciplinar español sobre la profilaxis de la infección respiratoria pediátrica por virus respiratorio sincitial. An Pediatr (Barc) 69 (2008) 63-71
4. Castro-Rodríguez J., and Rodrigo G. Efficacy of inhaled corticosteroids in infants and preschoolers with recurrent wheezing and asthma: a systematic review with meta-analysis. Pediatrics 123 (2009) e519-e525
5. Grupo de Hospitales Benazuza. Quimioprofilaxis con palivizumab en Andalucía. Resultados de la epidemia de VRS 2000 - 2001. An Esp Pediatr 56 (2002) 293-297
6. Groothuis J., Bauman J., Malinoski F., and Eggleston M. Strategies for prevention of RSV nosocomial infection. J Perinatol 28 (2008) 319-323
7. Kimpen J.L., and Schaad U.B. Treatment of respiratory syncytial virus bronchiolitis: 1995 poll of members of the European Society for Paediatric Infectious Diseases. Pediatr Infect Dis J 16 (1997) 479-481
8. New grades for recommendations from the Canadian Task Force on Preventive Health Care. CMAJ. 2003;169:207 - 8.
9. Atkins D., Best D., Briss P.A., Eccles M., Falck-Ytter Y., Flottorp S., et al. Grading quality of evidence and strength of recommendations. BMJ 328 (2004) 1490
10. Guyatt G.H., Oxman A.D., Vist G.E., Kunz R., Falck-Ytter Y., Alonso-Coello P., et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 336 (2008) 924-926
11. Guyatt G.H., Oxman A.D., Kunz R., Vist G.E., Falck-Ytter Y., and Schunemann H.J. What is "quality of evidence" and why is it important to clinicians?. BMJ 336 (2008) 995-998
12. Schunemann H.J., Oxman A.D., Brozek J., Glasziou P., Jaeschke R., Vist G.E., et al. Grading quality of evidence and strength of recommendations for diagnostic tests and strategies. BMJ 336 (2008) 1106-1110
13. Mansbach J.M., Emond J.A., and Camargo Jr. C.A. Bronchiolitis in US emergency departments 1992 to 2000: epidemiology and practice variation. Pediatr Emerg Care 21 (2005) 242-247
14. Bonillo Perales A., Díez Delgado Rubio J., Ortega Montes A., Infante Márquez P., Jiménez Liria M., Batllés Garrido J., et al., Comparación con el ImpactRSV Study Group. Antecedentes perinatales y hospitalización por bronquiolitis. An Esp Pediatr 53 (2000) 527-532
15. Carbonell-Estrany X., and Quero J. Hospitalization rates for respiratory syncytial virus infection in premature infants born during two consecutive seasons. Pediatr Infect Dis J 20 (2001) 874-879
16. Cilla G., Sarasua A., Montes M., Arostegui N., Vicente D., Perez-Yarza E., et al. Risk factors for hospitalization due to respiratory syncytial virus infection among infants in the Basque Country, Spain. Epidemiol Infect 134 (2006) 506-513
17. American Academy of Pediatrics (AAP) Subcommittee on Diagnosis and Management of Bronchiolitis. Diagnosis and management of bronchiolitis. Pediatrics 118 (2006) 1774-1793
18. SIGN. Bronchiolitis in children. A national clinical guideline. Available at: http://www.sign.ac.uk. 2006.
19. Bronchiolitis Guideline Team, Cincinnati Children's Hospital Medical Center. Evidence based clinical practice guideline for medical management of bronchiolitis in infants year of age or less presenting with a first time episode. Cincinnati: Cincinnati Children's Hospital Medical Center; 2005. [cited 22 August 2006]. Available from url: http://www.cincinnatichildrens.org/NR/rdonlyres/0B7B99D7-DB3E-4186-B2FC-71539E23421E/0/bronchiolitisguideline.pdf.
20. National Guideline Clearinghouse (NGC). Guideline Synthesis. Prevention, diagnosis and treatment of pediatric bronchiolitis. [en línea] [fecha de consulta: 09/05/2009]. Disponible en: http://www.guideline.gov/Compare/comparison.aspx?file=BRONCHIOLITIS1.inc.
21. Hartling L, Wiebe N, Russell K, Patel H, Klassen TP. Epinephrine for bronchiolitis. Cochrane Database Syst Rev. 2004:CD003123.
22. Spurling GK, Fonseka K, Doust J, Del Mar C. Antibiotics for bronchiolitis in children. Cochrane Database Syst Rev. 2007:CD005189.
23. Gadomski A.M., and Bhasale A.L. Broncodilatadores para la bronquiolitis. In: Gadomski A.M., and Bhasale A.L. (Eds). Broncodilatadores para la bronquiolitis (Revisión Cochrane traducida). La Biblioteca Cochrane Plus (2007), Update Software Ltd, Oxford. http://www.update-software.com Disponible a: http://www.update-software.com. (Traducida de The Cochrane Library. 2007. Chichester, UK: John Wiley & Sons, Ltd.)
24. Kellner J.D., Ohlsson A., Gadomski A.M., and Wang E.E. Bronchodilators for bronchiolitis. Cochrane Database Syst Rev (2000) CD001266
25. Everard M.L., Bara A., Kurian M., Elliott T.M., Ducharme F., and Mayowe V. Anticholinergic drugs for wheeze in children under the age of two years. Cochrane Database Syst Rev (2005) CD001279
26. Everard M.L., Bara A., Kurian M., Elliott T.M., and Ducharme F. Anticholinergic drugs for wheeze in children under the age of two years. Cochrane Database Syst Rev (2002) CD001279
27. Patel H., Platt R., and Lozano J. WITHDRAWN: Glucocorticoids for acute viral bronchiolitis in infants and young children. Cochrane Database Syst Rev (2008) CD004878
28. Patel H., Platt R., Lozano J.M., and Wang E.E. Glucocorticoids for acute viral bronchiolitis in infants and young children. Cochrane Database Syst Rev (2004) CD004878
29. McKean M., and Ducharme F. Inhaled steroids for episodic viral wheeze of childhood. Cochrane Database Syst Rev (2000) CD001107
30. Blom D., Ermers M., Bont L., van Aalderen W.M., and van Woensel J.B. Inhaled corticosteroids during acute bronchiolitis in the prevention of post-bronchiolitic wheezing. Cochrane Database Syst Rev (2007) CD004881
31. Perrotta C., Ortiz Z., and Roque M. Chest physiotherapy for acute bronchiolitis in paediatric patients between 0 and 24 months old. Cochrane Database Syst Rev (2007) CD004873
32. Perrotta C., Ortiz Z., and Roque M. Chest physiotherapy for acute bronchiolitis in paediatric patients between 0 and 24 months old. Cochrane Database Syst Rev (2005) CD004873
33. Wang E.E., and Tang N.K. WITHDRAWN: Immunoglobulin for preventing respiratory syncytial virus infection. Cochrane Database Syst Rev (2006) CD001725
34. Wang E.E., and Tang N.K. Immunoglobulin for preventing respiratory syncytial virus infection. Cochrane Database Syst Rev (2000) CD001725
35. Fuller H., and Del Mar C. Immunoglobulin treatment for respiratory syncytial virus infection. Cochrane Database Syst Rev (2006) CD004883
36. Ventre K., and Randolph A.G. Ribavirin for respiratory syncytial virus infection of the lower respiratory tract in infants and young children. Cochrane Database Syst Rev 1 (2007) CD000181
37. Ventre K., and Randolph A. Ribavirin for respiratory syncytial virus infection of the lower respiratory tract in infants and young children. Cochrane Database Syst Rev 4 (2004) CD000181
38. Zhang L.M.-S.R., Wainwright C., and Klassen T.P. Nebulized hypertonic saline solution for acute bronchiolitis in infants. Cochrane Database of Systematic Reviews (2008) CD006458 10.1002/14651858.CD006458.pub2
39. Ventre K., Haroon M., and Davison C. Surfactant therapy for bronchiolitis in critically ill infants. Cochrane Database Syst Rev 3 (2006) CD005150
40. Viswanathan M., King V.J., Bordley C., Honeycutt A.A., Wittenborn J., Jackman A.M., et al. Management of bronchiolitis in infants and children. Evid Rep Technol Assess (Summ) (2003) 1-5
41. Landau L.I. Current pharmacological treatments for bronchiolitis are useless. The case for the con's. Paediatr Respir Rev 7 Suppl 1 (2006) S101-S103
42. Barbi E., Faleschini E., and Bassanese S. Do we really need more trials about the efficacy of commonly used treatments for bronchiolitis?. Arch Pediatr Adolesc Med 159 (2005) 196-197 author reply 197
43. Calogero C., and Sly P.D. Acute viral bronchiolitis: to treat or not to treat-that is the question. J Pediatr 151 (2007) 235-237
44. Plint A., Johnson D., Patel H., Wiebe N., Correll R., Brant R., et al. Epinephrine and dexamethasone in children with bronchiolitis. N Engl J Med 360 (2009) 2079-2089
45. Lowell D.I., Lister G., Von Koss H., and McCarthy P. Wheezing in infants: the response to epinephrine. Pediatrics 79 (1987) 939-945
46. Schuh S., Coates A.L., Binnie R., Allin T., Goia C., Corey M., et al. Efficacy of oral dexamethasone in outpatients with acute bronchiolitis. J Pediatr 140 (2002) 27-32
47. Corneli H.M., Zorc J.J., Majahan P., Shaw K.N., Holubkov R., Reeves S.D., et al. A multicenter, randomized, controlled trial of dexamethasone for bronchiolitis. N Engl J Med 357 (2007) 331-339
48. Csonka P., Kaila M., Laippala P., Iso-Mustajarvi M., Vesikari T., and Ashorn P. Oral prednisolone in the acute management of children age 6 to 35 months with viral respiratory infection-induced lower airway disease: a randomized, placebo-controlled trial. J Pediatr 143 (2003) 725-730
49. American Academy of Pediatrics Committee on Infectious Diseases. Reassessment of the indications for ribavirin therapy in respiratory syncytial virus infections. Pediatrics 97 (1996) 137-140
50. Randolph A.G., and Wang E.E. Ribavirin for respiratory syncytial virus lower respiratory tract infection. A systematic overview. Arch Pediatr Adolesc Med 150 (1996) 942-947
51. Fitzgerald D.A., and Kilham H.A. Bronchiolitis: assessment and evidence-based management. Med J Aust 180 (2004) 399-404
52. Lozano J.M. Bronchiolitis. Clin Evid 4 (2005) 285-297
53. Kuppermann N., Bank D.E., Walton E.A., Senac Jr. M.O., and McCaslin I. Risks for bacteremia and urinary tract infections in young febrile children with bronchiolitis. Arch Pediatr Adolesc Med 151 (1997) 1207-1214
54. Henderson M., and Rubin E. Misuse of antimicrobials in children with asthma and bronchiolitis: a review. Pediatr Infect Dis J 20 (2001) 214-215
55. Field C.M., Connolly J.H., Murtagh G., Slattery C.M., and Turkington E.E. Antibiotic treatment of epidemic bronchiolitis-a double-blind trial. British Medical Journal (1966) 83-85
56. Friis B., Andersen P., Brenoe E., Hornsleth A., Jensen A., Knudsen F.U., et al. Antibiotic treatment of pneumonia and bronchiolitis. A prospective randomised study. Arch Dis Child 59 (1984) 1038-1045
57. Tahan F., Ozcan A., and Koc N. Clarithromycin in the treatment of RSV bronchiolitis: a double-blind, randomised, placebo-controlled trial. Eur Respir J 29 (2007) 91-97
58. Sarrell E.M., Tal G., Witzling M., Someck E., Houri S., Cohen H.A., et al. Nebulized 3% hypertonic saline solution treatment in ambulatory children with viral bronchiolitis decreases symptoms. Chest 122 (2002) 2015-2020
59. Mandelberg A., Tal G., Witzling M., Someck E., Houri S., Balin A., et al. Nebulized 3% hypertonic saline solution treatment in hospitalized infants with viral bronchiolitis. Chest 123 (2003) 481-487
60. Tal G., Cesar K., Oron A., Houri S., Ballin A., and Mandelberg A. Hypertonic saline/epinephrine treatment in hospitalized infants with viral bronchiolitis reduces hospitalization stay: 2 years experience. Isr Med Assoc J 8 (2006) 169-173
61. Kuzik B.A., Al-Qadhi S.A., Kent S., Flavin M.P., Hopman W., Hotte S., et al. Nebulized hypertonic saline in the treatment of viral bronchiolitis in infants. J Pediatr 151 (2007) 266-270 270 e1
62. Rimensberger P.C., Burek-Kozlowska A., Morell A., Germann D., Eigenmann A.K., Steiner F., et al. Aerosolized immunoglobulin treatment of respiratory syncytial virus infection in infants. The Pediatric Infectious Disease Journal (1996) 209-216
63. Downes J., Wood D., Striker T., and Haddad C. Acute respiratory failure in infants with bronchiolitis. Anesthesiology 29 (1968) 34-42
64. Zaw W., and McDonald J. Respiratory syncytial virus bronchiolitis in ex-preterm infants in the Scottish highlands: review of hospital admissions and an analysis of hospital cost. Scott Med J 48 (2003) 108-110
65. Lebel M., Gauthier M., Lacroix J., Rousseau E., and Buithieu M. Respiratory failure and mechanical ventilation in severe bronchiolitis. Arch Dis Child 64 (1989) 1431-1437
66. Beasley J., and Jones S. Continuous positive airway pressure in bronchiolitis. Br Med J (Clin Res Ed) 283 (1981) 1506-1508
67. Soong W., Hwang B., and Tang R. Continuous positive airway pressure by nasal prongs in bronchiolitis. Pediatr Pulmonol 16 (1993) 163-166
68. Al-balkhi A., Klonin H., Marinaki K., Southall D.P., Thomas D.A., Jones P., et al. Review of treatment of bronchiolitis related apnoea in two centres. Arch Dis Child 90 (2005) 288-291
69. Duval E., Leroy P., Gemke R., and van Vught A. High-frequency oscillatory ventilation in RSV bronchiolitis patients. Respir Med 93 (1999) 435-440
70. Flamant C., Hallalel F., Nolent P., Chevalier J.Y., and Renolleau S. Severe respiratory syncytial virus bronchiolitis in children: from short mechanical ventilation to extracorporeal membrane oxygenation. Eur J Pediatr 164 (2005) 93-98
71. Khan J., Kerr S., Tometzki A., Tyszczuk L., West J., Sosnowski A., et al. Role of ECMO in the treatment of respiratory syncytial virus bronchiolitis: a collaborative report. Arch Dis Child Fetal Neonatal Ed 73 (1995) 91-94
72. Thia L.P., McKenzie S.A., Blyth T.P., Minasian C.C., Kozlowska W.J., and Carr S.B. Randomised controlled trial of nasal continuous positive airways pressure (CPAP) in bronchiolitis. Arch Dis Child 93 (2008) 45-47
73. Martinón-Torres F., Rodríguez-Núñez A., and Martinón-Sánchez J.M. Heliox therapy in infants with acute bronchiolitis. Pediatrics 109 (2002) 68-73
74. Iglesias Fernández C., Huidobro Fernández B., Míguez Navarro C., Guerrero Soler M., Vázquez López P., and Marañón Pardillo R. Heliox como fuente de nebulización del tratamiento broncodilatador en lactantes con bronquiolitis. An Pediatr (Barc) 70 (2009) 40-44
75. Luchetti M., Ferrero F., Gallini C., Natale A., Pigna A., Tortorolo L., et al. Multicenter, randomized, controlled study of porcine surfactant in severe respiratory syncytial virus-induced respiratory failure. Pediatr Crit Care Med 3 (2002) 261-268
76. Luchetti M., Casiraghi G., Valsecchi R., Galassini E., and Marraro G. Porcine-derived surfactant treatment of severe bronchiolitis. Acta Anaesthesiol Scand 42 (1998) 805-810
77. Tibby S.M., Hatherill M., Wright S.M., Wilson P., Postle A.D., and Murdoch I.A. Exogenous surfactant supplementation in infants with respiratory syncytial virus bronchiolitis. Am J Respir Crit Care Med 162 (2000) 1251-1256
78. Wankum P., Graff G., and Tobias J. A comparison of the effects of nebulized albuterol, L-epinephrine, and saline on the pulmonary mechanics in RSV bronchiolitis [abstract]. American Journal of Respiratory and Critical Care Medicine (2000) A340
79. Johnston D., and Kuzemko J. Virus induced apnoea and theophylline. Lancet 340 (1992) 1352
80. DeBuse P., and Cartwright D. Respiratory syncytial virus with apnoea treated with theophylline. Med J Aust 2 (1979) 307-308
81. Nasr S.Z., Strouse P.J., Soskolne E., Maxvold N.J., Garver K.A., Rubin B.K., et al. Efficacy of recombinant human deoxyribonuclease I in the hospital management of respiratory syncytial virus bronchiolitis. Chest 120 (2001) 203-208
82. Sung R.Y.T., Yin J., Oppenheimer S.J., Tam J.S., and Lau J. Treatment of respiratory sycytial virus infection with recombinant interferon alfa-2A. Arch Dis Child (1993) 440-442
83. Ermers M., Rovers M., Van Voensel J., Kimpen J., Bont J., and Group. obotRCS. The effect of high dose inhaled corticosteroids on wheeze in infants alter respiratory syncytial virus infection: randomised double blind placebo controlled trial. BMJ 338 (2009) b897
84. Bisgaard H. A randomized trial of montelukast in respiratory syncytial virus postbronchiolitis. Am J Respir Crit Care Med 167 (2003) 379-383
85. Bisgaard H., Flores-Nuñez A., Goh A., Azimi P., Halkas A., Malice M., et al. Study of montelukast for the treatment of respiratory symptoms of post-respiratory syncytial virus bronchiolitis in children. Am J Respir Crit Care Med 178 (2008) 854-860
86. Martinez F., Wright A., Taussig L., Holberg C., Halonen M., Morgan W., and The Group Health Medical Associates. Asthma and wheezing in the first six years of life. N Engl J Med 332 (1995) 133-138
87. Taussig L., Wright A., Holberg C., Halonen M., Morgan W., and Martinez F. Tucson Children's Respiratory Study: 1980 to present. J Allergy Clin Immunol 111 (2003) 661-675
88. Castro-Rodríguez J., Holberg C., Wrigth A., and Martínez F. A Clinical Index to define risk of asthma in young children with recurrent wheezing. Am J Respir Crit Care Med 162 (2000) 1403-1406
89. Guilbert T., Morgan W., Zeiger R., Bacharier L., Boehmer S., Krawiec M., et al. Atopic characteristics of children with recurrent wheezing at high risk for the development of childhood asthma. J Allergy Clin Immunol 114 (2004) 1282-1287
90. The PREVENT Study Group. Reduction of respiratory syncytial virus hospitalization among premature infants and infants with bronchopulmonary dysplasia using respiratory syncytial virus immune globulin prophylaxis. Pediatrics 99 (1997) 93-99
91. Groothuis J.R., Simoes E.A., Levin M.J., Hall C.B., Long C.E., Rodriguez W.J., et al., The Respiratory Syncytial Virus Immune Globulin Study Group. Prophylactic administration of respiratory syncytial virus immune globulin to high-risk infants and young children. N Engl J Med 329 (1993) 1524-1530
92. The IMpact-RSV Study Group. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics 102 (1998) 531-537
93. Meissner H.C. Uncertainty in the management of viral lower respiratory tract disease. Pediatrics 108 (2001) 1000-1003
94. Feltes T.F., Cabalka A.K., Meissner H.C., Piazza F.M., Carlin D.A., Top Jr. F.H., et al. Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease. J Pediatr 143 (2003) 532-540
95. Pedraz C., Carbonell-Estrany X., Figueras-Aloy J., and Quero J. Effect of palivizumab prophylaxis in decreasing respiratory syncytial virus hospitalizations in premature infants. Pediatr Infect Dis J 22 (2003) 823-827
96. Medrano C., Garcia-Guereta L., Grueso J., Insa B., Ballesteros F., Casaldaliga J., et al. Respiratory infection in congenital cardiac disease. Hospitalizations in young children in Spain during 2004 and 2005: the CIVIC Epidemiologic Study. Cardiol Young 17 (2007) 360-371
97. Singleton R., Dooley L., Bruden D., Raelson S., and Butler J.C. Impact of palivizumab prophylaxis on respiratory syncytial virus hospitalizations in high risk Alaska Native infants. Pediatr Infect Dis J 22 (2003) 540-545
98. Singleton R.J., Bruden D., Bulkow L.R., Varney G., and Butler J.C. Decline in respiratory syncytial virus hospitalizations in a region with high hospitalization rates and prolonged season. Pediatr Infect Dis J 25 (2006) 1116-1122
99. Henckel E., Luthander J., Berggren E., Kapadia H., Naver L., Norman M., et al. Palivizumab prophylaxis and hospitalization for respiratory syncytial virus disease in the Stockholm infant population, 1999 through 2002. Pediatr Infect Dis J 23 (2004) 27-31
100. Lacaze-Masmonteil T., Seidenberg J., Mitchell I., Cossey V., Cihar M., Csader M., et al. Evaluation of the safety of palivizumab in the second season of exposure in young children at risk for severe respiratory syncytial virus infection. Drug Saf 26 (2003) 283-291
101. Mitchell I., Tough S., Gillis L., and Majaesic C. Beyond randomized controlled trials: a "real life" experience of respiratory syncytial virus infection prevention in infancy with and without palivizumab. Pediatr Pulmonol 41 (2006) 1167-1174
102. Embleton N.D., Harkensee C., and McKean M.C. Palivizumab for preterm infants. Is it worth it?. Arch Dis Child Fetal Neonatal Ed 90 (2005) F286-F289
103. Embleton N.D., Dharmaraj S.T., and Dehspande S. Cost-effectiveness of palivizumab in infancy. Expert Review of Pharmacoeconomics and Outcomes Research 7 (2007) 445-458
104. Chen C.H., Lin Y.T., Yang Y.H., Wang L.C., Lee J.H., Kao C.L., et al. Ribavirin for respiratory syncytial virus bronchiolitis reduced the risk of asthma and allergen sensitization. Pediatric Allergy and Immunology 19 (2008) 166-172
105. Kamal-Bahl S., Doshi J., and Campbell J. Economic analyses of respiratory syncytial virus immunoprophylaxis in high-risk infants: a systematic review. Arch Pediatr Adolesc Med 156 (2002) 1034-1041
106. Dunfield L., and Mierzwinski-Urban M. Palivizumab prophylaxis against respiratory syncytial virus. Ottawa: Canadian Agency for Drugs and Technologies in Health (CADTH) (2007) 17
107. Lofland J.H., O'Connor J.P., Chatterton M.L., Moxey E.D., Paddock L.E., Nash D.B., et al. Palivizumab for respiratory syncytial virus prophylaxis in high-risk infants: a cost-effectiveness analysis. Clin Ther 22 (2000) 1357-1369
108. Schrand L.M., Elliott J.M., Ross M.B., Bell E.F., and Mutnick A.H. A cost-benefit analysis of RSV prophylaxis in high-risk infants. Ann Pharmacother 35 (2001) 1186-1193
109. Farina D., Rodriguez S.P., Bauer G., Novali L., Bouzas L., Gonzalez H., et al. Respiratory syncytial virus prophylaxis: cost-effective analysis in Argentina. Pediatr Infect Dis J 21 (2002) 287-291
110. Chiroli S. Cost-efficcy analysis of palivizumab in the prevention of respiratory syncytial virus infections in young children with hemodynamically significant congenital heart disease. I. Ital J Pediatr 31 (2005) 188-194
111. Lazaro y de Mercado P., Figueras Aloy J., Domenech Martinez E., Echaniz Urcelay I., Closa Monasterolo R., Wood Wood M.A., et al. La eficiencia (coste-efectividad) de palivizumab como profilaxis para la infección por virus respiratorio sincitial en prematuros de 32 - 35 semanas en España. An Pediatr (Barc) 65 (2006) 316-324
112. Lazaro Y De Mercado P., Figueras J., Domenech E., Closa R., Echaniz I., Wood M.A., et al. Cost-effectiveness of palivizumab in preventing respiratory syncytial virus in premature infants and children with chronic lung disease in Spain. Pharmacoeconomics-Spanish Research Articles 4 (2007) 59-70
113. Nuijten M.J., Wittenberg W., and Lebmeier M. Cost effectiveness of palivizumab for respiratory syncytial virus prophylaxis in high-risk children: a UK analysis. Pharmacoeconomics 25 (2007) 55-71
114. Chirico G., Ravasio R., and Sbarigia U. Cost-utility analysis of palivizumab in Italy: results from a simulation model in the prophylaxis of respiratory syncyial virus infection (RSV) among high-risk preterm infants. Ital J Pediatr 35 (2009) 4 10.1186/124-788-35-4
115. Joffe S., Ray G.T., Escobar G.J., Black S.B., and Lieu T.A. Cost-effectiveness of respiratory syncytial virus prophylaxis among preterm infants. Pediatrics 104 (1999) 419-427
116. Numa A. Outcome of respiratory syncytial virus infection and a cost-benefit analysis of prophylaxis. J Paediatr Child Health 36 (2000) 422-427
117. Vogel A.M., McKinlay M.J., Ashton T., Lennon D.R., Harding J.E., Pinnock R., et al. Cost-effectiveness of palivizumab in New Zealand. J Paediatr Child Health 38 (2002) 352-357
118. Yount L.E., and Mahle W.T. Economic analysis of palivizumab in infants with congenital heart disease. Pediatrics 114 (2004) 1606-1611